SCHEMBL6287220

SCHEMBL6287220

O=C(Cc1c[nH]c2ccccc12)N[C@@H](Cc1ccc(OCc2ccccc2)cc1)C(=O)Nc1ccc(C(c2ccc(NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)Cc3c[nH]c4ccccc34)cc2)c2ccc(NC(=O)[C@H](Cc3ccc(OCc4ccccc4)cc3)NC(=O)Cc3c[nH]c4ccccc34)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ECE1 P42892 2/20 0.57
KDM1A O60341 1/20 0.53
MAOA P21397 1/20 0.53
ERAP2 Q6P179 1/20 0.50
ERAP1 Q9NZ08 1/20 0.50
LNPEP Q9UIQ6 1/20 0.50
PTPN1 P18031 2/20 0.49
HDAC1 Q13547 7/20 0.49
HDAC8 Q9BY41 5/20 0.49
HDAC3 O15379 4/20 0.49
HDAC4 P56524 4/20 0.49
HDAC7 Q8WUI4 4/20 0.49
HDAC2 Q92769 4/20 0.49
HDAC10 Q969S8 4/20 0.49
HDAC11 Q96DB2 4/20 0.49
HDAC6 Q9UBN7 4/20 0.49
HDAC9 Q9UKV0 4/20 0.49
HDAC5 Q9UQL6 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6290992 0.92 HDAC8 (0.54) ECE1KDM1AMAOAHDAC1HDAC8
SCHEMBL6287093 0.89 SLC6A2 (0.53) KDM1AMAOAERAP2ERAP1LNPEP
SCHEMBL6287532 0.86 S1PR1 (0.54) ECE1KDM1AMAOAHDAC1HDAC8
SCHEMBL6287783 0.85 HDAC8 (0.61) KDM1AMAOAHDAC1HDAC8HDAC3
SCHEMBL6287918 0.84 FPR2 (0.52) KDM1AMAOAHDAC1HDAC8HDAC3
SCHEMBL6290249 0.83 HDAC8 (0.50) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6287920 0.83 BMP1 (0.53) ECE1KDM1AMAOAHDAC1HDAC8
Trifluoroacetic Acid SCHEMBL6287362 0.82 LMNA (0.49) HDAC1HDAC8HDAC3HDAC4HDAC7
SCHEMBL6287655 0.82 HDAC1 (0.50) KDM1AMAOAHDAC1HDAC8HDAC3
SCHEMBL6284047 0.82 BMP1 (0.56) ECE1KDM1AMAOAHDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6887890-B2 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2005-05-03 US disclosed
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-08-28 US disclosed
EP-1291341-A1 COMPOUNDS EXHIBITING THROMBOPOIETIN-LIKE ACTIVITIES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2003-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162724-A1 Compounds exhibiting thrombopoietin-like activities MPL, THPO, TEK ECE1 203/4885KDM1A 2566/4885MAOA 1862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.